Medical Industry Feature

ReachMD
  • 4.0 (1)
  • SCIENCE
  • UPDATED DAILY

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

  1. APR 20

    From Monoamines to Neurocircuits: Our Evolving Understanding of Depression

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joseph Goldberg, MD Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.

    11 min

  2. APR 1

    Neuroplasticity: A Potential Target for the Treatment of Depression

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Madhukar H. Trivedi, MD The brain is constantly changing as a result of experience, stress, emotional processing, learning, and memory.1 And neuroplasticity adds another layer to these approaches by focusing on what’s actually changing in the brain.2 Tune in with Dr. Charles Turck as he speaks with Dr. Madhukar Trivedi, Founding Director of the Center for Depression Research and Clinical Care and Chief of the Division of Mood Disorders at the University of Texas Southwestern Medical Center in Dallas, Texas. References: Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77. Mateos-Aparicio P, Rodriguez-Moreno A. The impact of studying brain plasticity. Front Cell Neurosci. 2019;13:66.

    15 min

  3. MAR 30

    Breakthrough Technology Improves Concussion Assessment and Player Safety

    Guest: Thomas S. Bottiglieri, D.O. On this episode of Advances in Care, host Erin Welsh sits down with Dr. Thomas Bottiglieri, Chief of the Primary Care Sports Medicine Division at NewYork-Presbyterian and Columbia, to discuss the evolving landscape of concussion care—from prevalence to emerging diagnostic breakthroughs. With over 2 million estimated concussions occurring annually in the United States and many of them affecting young athletes, Dr. Bottiglieri and his colleagues have sought to develop a more accurate and accessible way to objectively diagnose concussion. While a single injury may not cause long-term issues, research shows that repeated head trauma—and lack of proper care—can lead to premature neurodegeneration. During their research to improve diagnostic measures, Dr. Bottiglieri and his team discovered a biomarker associated with severe concussions: a subtle tremor of the head and neck that becomes amplified when a concussed patient tries to visually focus on a target. This discovery led to the development of ProScope, an innovative eye-tracking software tool that measures head and neck stability and can detect the diagnostic biomarker with over 80% sensitivity. With the advent of these tools, clinicians can now, for the first time, objectively measure concussion. A former competitive athlete himself, Dr. Bottiglieri hopes that the ProScope tool …

    18 min

  4. MAR 24

    Groundbreaking AI Models Transform Cardiovascular Diagnosis

    Guest: Pierre Elias, M.D. Learn how Dr. Pierre Elias and his team at NewYork-Presbyterian and Columbia have established a deep learning lab called CRADLE, which uses basic medical imaging, EKGs, and echocardiograms to build advanced AI models that help identify all forms of structural heart disease, including cardiac amyloidosis and valvular regurgitation. These tools not only improve screening access but enable early detection. © 2026 NewYork-Presbyterian

    5 min

  5. MAR 13

    Insights for Postmenopausal Osteoporosis Patients at Very High Risk of Fracture

    Host: Jennifer Caudle, DO, FACOFP Guest: Felicia Cosman, MD Starting with the presence of a prior fracture, advancing age, and bone mineral density, there are numerous factors that increase the risk of fracture in postmenopausal women.1 But despite these common predictors, treatment rates of osteoporosis in postmenopausal women have consistently remained low.2 For instance, in the last decade, less than 10% of women aged 50 years and older have received treatment for their osteoporosis.2 To help address these unmet needs, Dr. Jennifer Caudle speaks with Dr. Felicia Cosman about best practices for diagnosing and treating postmenopausal osteoporosis patients who are at a very high risk of fracture. Dr. Cosman is a Professor of Medicine Emerita at Columbia University Vagelos College of Physicians and Surgeons in New York. References: Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889-1897. Data on file, Amgen; 2024.

    12 min

  6. MAR 6

    Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice

    Host: Charles Turck, PharmD, BCPS, BCCCP Guest: George Grossberg, MD Guest: Angela Sanford, MD, CMD Nearly half of patients living with dementia due to Alzheimer’s disease will experience agitation during the course of illness.1 In June 2025, expert panel recommendations on identifying and managing agitation in Alzheimer’s dementia were published in Postgraduate Medicine. Learn more about these recommendations as Dr. Charles Turck, Dr. George Grossberg, and Dr. Angela Sanford explore how clinicians can implement them in practice. Dr. Grossberg is the Inaugural Henry and Amelia Nasrallah Endowed Professor as well as the Director of the Division of Geriatric Psychiatry and Behavioral Neuroscience at the Saint Louis University School of Medicine. Dr. Sanford is a Professor in the Division of Geriatric Medicine in the Department of Internal Medicine at the Saint Louis University School of Medicine. Drs. Grossberg and Sanford are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. The expert panel and subsequent publication were sponsored by Otuska and Lundbeck -- not an independent entity. References: Grossberg GT, Sanford A, Montano CB, et al. A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel. Postgrad Med. 2025;137(6):469–485.

    15 min

  7. FEB 13

    Gene Therapy, the Future of Eye Care?

    Guest: Courtney Crawford, MD, FACS Guest: Raj Maturi, MD While anti-VEGF therapy can deliver vision gains with consistent, frequent injections in clinical trials, it may be challenging to sustain this in real-world practice.1 Ocular gene therapy could be a potential option for patients with neovascular age-related macular degeneration if approved. With this approach, transgenes are delivered to the eye by adeno-associated viruses (AAVs).2-4 Learn more with Drs. Courtney Crawford and Raj Maturi, who shared their perspectives on investigational gene therapy, patient conversations, and surgical considerations at the 2025 American Academy of Ophthalmology annual meeting in Orlando, Florida. Dr. Crawford is a board-certified retina specialist and founder of Star Retina in Burleson, Texas. He previously served for 10 years as a physician in the U.S. Army, where he attained the rank of Lieutenant Colonel. Dr. Maturi is a board-certified retina specialist at the Midwest Eye Institute and founder of Retina Partners Midwest in Carmel, Indiana, where he focuses on macular, retina, and vitreous care. References: Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing visual outcomes in patients with neovascular age-related macular degeneration: the potential value of sustained anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2023;54:654–659. Petrich J, Marchese D, Jenkins C, Storey M, Blind J. …

    14 min

  8. FEB 12

    Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers

    Host: Yuval Zabar, MD Guest: Michelle Mielke, PhD Guest: Henrik Zetterberg, MD, PhD For the latest insights on tau and neurodegeneration biomarkers in Alzheimer’s disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade’, the current use of tau and neurodegeneration biomarkers in tracking disease progression, and how the AD biomarker landscape may evolve over time. Doctor Mielke is a Professor of Epidemiology and Neurology at the Wake Forest University School of Medicine, and Professor Zetterberg is a Professor of Neurochemistry at the University of Gothenburg. To learn more about tau in Alzheimer’s disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only.

    45 min
See All (33)

About

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Information

  • Creator
    ReachMD
  • Years Active
    2014 - 2026
  • Episodes
    33
  • Rating
    Clean
  • Copyright
    © Copyright 2026 ReachMD. All rights reserved.
  • Show Website
    Medical Industry Feature

More From ReachMD